← Back to patent-cliff list
177Lu-HTK03170
Tier C — Watch / trade177Lu-HTK03170
British Columbia Cancer Agency
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Radiopharmaceutical
Type
Targets：PSMA
Indications (approved)：Prostate cancer, Castration-resistant prostate cancer
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of 177Lu-HTK03170?
Approved indications include: Prostate cancer, Castration-resistant prostate cancer.
When does the 177Lu-HTK03170 patent expire?
No public expiry year is available for 177Lu-HTK03170 yet; this page updates once verified.
How do I get a quote for 177Lu-HTK03170 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02